General recommendation for assessment and management on the risk of glucocorticoid-induced osteonecrosis in patients with COVID-19

• DOI: 10.1016/j.jot.2021.09.005
• Publication Date: 2021-10-22T07:34:53Z
• Authors: Wenlong Li; Zeqing Huang; Biao Tan; Gang Chen; Xugui Li; Kan Xiong; Ruizheng Zhu; Ruihan Li; Shuwen Li; Hengli Ye; Zhi Liang; Xiaojun Dong; Shijing Zhou; Song Chen; Haixiang Xi; Hao Cheng; Rongpeng Xu; Shenghao Tu; Zhe Chen; Lihua Qi; Jiandong Song; Ruoran Xiao; Huilan Liu; Qian Nan; Huiyong Yu; Hongsheng Cui; Yanguang Shen; Chengxiang Wang; Na Lin; Yanqiong Zhang; Weiheng Chen
• Keywords: Disease prevention and control; 0301 basic medicine; 03 medical and health sciences; 0302 clinical medicine; Coronavirus disease 2019; Severe acute respiratory syndrome; RC925-935; Osteonecrosis; Original Article; Diseases of the musculoskeletal system; Glucocorticoids; 3. Good health

Coronavirus disease 2019 (COVID-19) is a disaster in human medical history and glucocorticoids remain the most promising therapy. Osteonecrosis caused by reduced intraosseous blood flow to bones joints, which will rapidly induce joint destruction. Approximately one-third patients with severe acute respiratory syndrome (SARS) who received high cumulative doses long treatment durations of occurred osteonecrosis. Considering similarity SARS COVID-19 on their pathogen, clinical characteristics, therapeutic strategies, it particularly desirable investigate whether osteonecrosis become common sequela among convalescent patients.